QML Pathology

What QML Pathology does

QML Pathology is a Queensland-headquartered diagnostic pathology provider operating as a trading name of Healius Pathology Pty Ltd, itself a wholly-owned subsidiary of Healius Ltd, a top 100 ASX-listed healthcare group. Founded in the 1920s by Dr Noel Gutteridge and Dr James Duhig and formally amalgamated in 1974, the business runs over 600 collection centres across Queensland and northern New South Wales with access to 2,000+ locations nationally via the Healius network, supported by a central laboratory in Murarrie (Brisbane), a mobile/home collection service, and NATA-accredited facilities certified to ISO 15189 and ISO 17025. Its service portfolio spans anatomical pathology, cytopathology, chemical pathology, haematology, immunology, microbiology, and genetics, plus specialised clinical services such as the Warfarin Care Clinic, therapeutic venesection, iron infusions, biological monitoring, accredited drug and alcohol testing (AS/NZS 4308 and 4760), and Phases I–IV clinical trial laboratory services delivered through a dedicated project management team and the Medway Clinical Trials Portal.

The core technology stack is the Medway ecosystem: Medway Results for real-time clinician access to pathology data, Medway Practice for consumables and courier ordering, the proprietary Healius MQLink EDI software used by over 20,000 Australian doctors for automated result download into clinical software via HL7 and PIT, eReferrals for paperless GP-to-lab ordering, and a Telehealth eRequest capability for remote consultations. AI-assisted interpretation is layered into the diagnostic workflow as a pathologist-support tool with mandated human oversight. The company monetises through Medicare bulk-billed MBS pathology tests (the dominant revenue stream), out-of-pocket fees for non-Medicare tests and self-request tests, subscription and annual fees for chronic-disease management services such as the Warfarin Care Clinic, per-test and project-based commercial billing for employer drug and alcohol testing and employee wellness screening, and multi-year clinical trial contracts typically augmented by free consumables supply. Customer segments span individual patients, GPs and specialist clinicians, corporate and industrial employers, and pharmaceutical and biotech research sponsors, with go-to-market executed through healthcare-provider referrals, online booking, dedicated commercial sales, and digital integration with clinician practice management systems.

Name

QML Pathology

Legal name

Healius Pathology Pty Ltd

Website

https://qml.com.au

Company type

Private

Founded year

1920

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

QML Pathology is a Queensland-based diagnostic pathology provider operating as a trading name of Healius Pathology Pty Ltd. It serves patients, clinicians, employers, and research sponsors through 600+ collection centres, NATA-accredited laboratories, and the integrated Medway digital platform including MQLink EDI.

Ownership category

akta.pro rank

Product category

Diagnostic Pathology Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI), Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)

Keywords

• Diagnostic pathology services
• Medical laboratory testing
• Workplace drug testing
• Clinical trials laboratory
• Occupational health screening

Headquarters

HQ city

Brisbane

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Medicare Bulk-Billed Pathology Services: Bulk billing for all pathology tests covered under the Medicare Benefits Schedule (MBS). When tests are requested appropriately by doctors, patients do not pay out-of-pocket
2. Out-of-Pocket Patient Services: Payment required for tests not covered by Medicare, including insurance, employment, visa/immigration, pre-employment, legal purposes, certain specialized tests, non-Medicare eligible patients, and privately billed tests
3. Commercial Drug & Alcohol Testing: Accredited workplace drug and alcohol testing services including urine, oral fluid, and hair testing following AS4308 and AS4760 standards. Revenue from employers and organizations
4. Employee Wellness & Occupational Health: Pre-employment health checks, ongoing wellness screening, occupational risk testing for chemicals and infectious diseases, provided to employers and organizations
5. Clinical Trials Laboratory Services: Comprehensive lab services for clinical trials (Phases I-IV) supporting pharmaceutical, biotech, and research organizations with testing, logistics, and data management
6. Consumables Supply: Supply of bulk consumables for clinical trials and workplace testing programs free of charge as part of service package
7. Warfarin Care Clinic Services: Warfarin dosing management with registration fee and annual fee for enrolled patients. Services include INR monitoring, dose adjustments, and patient support. DVA billed directly for eligible cardholders
8. Special Test Clinic Services: Therapeutic Venesection (annual fee), Iron Infusion, and Short Synacthen Test services with upfront payment required from patients
9. Self-Request Pathology Tests: Direct-to-consumer pathology testing for patients 16+ without doctor referral. Full cost paid at collection as not eligible for Medicare rebates

Pricing tiers

Go-to-market motion3 records

Distribution channels7 records

Marketing channels7 records

Core offering

QML Pathology is a private pathology diagnostics provider that collects patient specimens and performs diagnostic laboratory testing across anatomical pathology, cytopathology, chemical pathology, haematology, immunology, microbiology, and genetics. It also offers commercial services including accredited drug and alcohol testing, employee wellness screening, biological monitoring for hazardous chemical exposure, and clinical trial laboratory services for pharmaceutical and biotech research organizations. Digital platforms (Medway Results, Medway Practice, MQLink EDI) enable clinicians to access results in real-time and integrate them with practice management systems.

Product overview

QML Pathology is a leading Queensland pathology provider offering a comprehensive diagnostic testing platform. The core offering is pathology diagnostic testing services spanning anatomical pathology, cytopathology, chemical pathology, haematology, immunology, microbiology, and genetics, delivered through a network of over 600 collection centres across Queensland (2,000+ nationally through the Healius network). The patient-facing portfolio includes online appointment booking, Medway Results for real-time access, and self-request pathology tests for adults 16+. The clinician-facing digital ecosystem comprises Healius MQLink (EDI software for clinical software integration), Medway Results and Medway Practice portals, eReferrals, Telehealth pathology requests, and Medway Clinical Trials Portal. Specialised service modules include the Warfarin Care Clinic (40+ years), mobile collections, special test clinics (therapeutic venesection, iron infusions, Synacthen tests), and Anti-D Immunoglobulin ordering. Commercial services include accredited drug and alcohol testing (NATA AS4308/AS4760), employee wellness screening, biological monitoring testing, and clinical trials support. QML Pathology is part of Healius Pathology Pty Ltd, a top 100 ASX-listed entity operating multiple pathology brands nationwide including Laverty, Dorevitch, Abbott, Western Diagnostic, and TML Pathology.

Differentiator

Problem solved

Functional benefit

Brands

• Healius Pathology: The broader network of specialist pathologist practices that QML Pathology is part of, providing governance and support infrastructure.

Products and services

• QML Pathology Diagnostic Testing Services
• Drug & Alcohol Testing Services

Quantifiable outcome

• Over 600 collection centres in Queensland with 2,000+ nationally through Healius network
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core, strategic and minor.

• Healius Pathology Pty LtdcoreStrategic or Co-development PartnerQML Pathology is a trading name of Healius Pathology Pty Ltd (ACN 007 190 043), part of the Healius Ltd (ACN 064 530 516) group. Healius is a top 100 ASX publicly listed entity providing governance, support infrastructure, and the national network of pathology practices including Laverty Pathology (NSW/ACT), Dorevitch Pathology (Victoria), Abbott Pathology (SA), Western Diagnostic Pathology (WA/NT), TML Pathology (Tasmania), and others.
• Clinical Software VendorscoreTechnology or IntegrationIntegration partnerships with all major desktop clinical software systems in Australia. MQLink EDI software enables automatic download of QML pathology results into clinician practice management systems. Supported by specialist EDI team with phone, remote desktop, and on-site support.
• Agilex BiolabsstrategicStrategic or Co-development PartnerSpecialized bioanalytical testing partner with FDA-inspected facilities for clinical trials. Provides advanced bioanalytical testing services as part of the Healius clinical trials service offering.
• Reference Laboratories NetworkcoreTechnology or IntegrationAccess to large network of NATA-certified reference laboratories for specialized testing beyond QML's internal capabilities. Supports access to over 2,000 tests and TGA-approved services for clinical trials.
• Occupational Health ConsultantsminorChannel Partner/ Reseller/ DistributorFor industries without previous experience in drug testing, QML recommends contacting occupational health consultants or accredited laboratories for guidance on setting up and managing testing procedures.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Laverty Pathology: Direct sister pathology brand within Healius Ltd serving NSW/ACT with the same diagnostic testing, collection centre network, and Medway platform. Same parent makes them the closest operational and commercial peer.
• Dorevitch Pathology: Healius-owned pathology brand serving Victoria with comparable clinical laboratory services, collection centre network, and Medway integration. Operates with the same revenue model and clinical capability stack as QML.
• Abbott Pathology: Healius sister brand serving South Australia with full-service pathology testing, bulk billing, and clinical trial services. Closely comparable in operating model and product offering to QML.
• Western Diagnostic Pathology: Healius pathology brand for WA/NT, offering the same diagnostic services, collection centre network, and clinical trial capabilities as QML. Sister brand under common infrastructure.
• Clinical Labs: Australian pathology provider (owned by TPG Capital) with comparable diagnostic services, bulk billing model, and commercial testing offerings. Operates in several states and competes with QML for both patient and clinician customers.
• Douglass Hanly Moir Pathology: Sonic Healthcare subsidiary offering full pathology diagnostics, collection centres, and clinical trials support in NSW/ACT. Operates with comparable scale and product breadth to QML in its market.
• Sullivan Nicolaides Pathology: Long-established Sonic Healthcare pathology brand serving Queensland and northern NSW — directly overlapping QML's geographic footprint. Major competitor for GP referrals, bulk-billed tests, and specialist pathology work.

Broad incumbents

• Sonic Healthcare: ASX-listed global pathology giant operating multiple Australian brands (Douglass Hanly Moir, Melbourne Pathology, Sullivan Nicolaides). Directly competes with QML on Medicare-billed pathology, commercial testing, and clinical trials nationally.

Emerging players

• 4Cyte Pathology: Privately-held Australian pathology provider rapidly expanding collection centres and bulk-billed services. Directly competes with QML for GP referrals in overlapping geographies and has been gaining market share through competitive billing practices.
• i-screen: Australian D2C pathology provider specializing in self-requested health screening tests ordered online. Competes with QML's self-request offering and represents the emerging consumer-facing model that could erode QML's traditional referral base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/qmlpathology

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QML Pathology